2018 CEO Sernova

<p>Oct 10, 2018 07:51 PM &nbsp;Phil Toleikis &nbsp;CEO &nbsp;in NYC &nbsp;Investor Conf.</p>

<p>

first in human in Canada... finished study.</p>

<p>

US &nbsp;phase 1/2 study... cleared by FDA. &nbsp;initiate in &nbsp;2018..</p>

<p>

preventing fibrosis... &nbsp;cell pouch...</p>

<p>

pouch is v porous... &nbsp;&nbsp;vasculature grows into the pouch &nbsp;and

do not put &nbsp;cells in for 2 weeks.</p>

<p>

immune protection is separate...</p>

<p>

200 day &nbsp;protection...</p>

<p>

highly purified islets...</p>

<p>

do &nbsp;human islets first &nbsp;before &nbsp;stem cell tech.</p>

<p>

combo of cell pouch and &nbsp;immune protection;</p>

<p>

Edmondton Protocol;</p>

<p>

massive inflammation and destruc of cells;</p>

<p>

we can use &nbsp;a lot fewer cells;</p>

<p>

non human primates... &nbsp;pouch can be put anywhere... highly &nbsp;vascularized... around the waist;

did implants in pigs; &nbsp;</p>

<p>

Q &nbsp;abt Viacyte and other companies;</p>

<p>

most companies &nbsp;combine &nbsp;the immune function &nbsp;with the device...</p>

<p>

we first to create &nbsp;separate &nbsp;vascular bed;</p>

<p>

WHEN on mkt: &nbsp;&nbsp;3 years... maybe for &nbsp;pt most in need...</p>

<p>

already working on &nbsp;porcine &nbsp;islets....</p>

<p>

min 21: Tolekis: We are first to show that we can make islets survive &nbsp;(and Viacyte has not yet)</p>

<p>

min 22: &nbsp;we need to do with 3M but our competitors do with 100M.

our investors have families with DM.</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>

<p>

&nbsp;</p>